ZLZoe Lombardi
Zoe Lombardi
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zoe Lombardi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Tubita
Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy
24 shared publications Alessio Menconi
24 shared publicationsAtanasio Pandiella
24 shared publicationsAzucena Esparís-Ogando
24 shared publicationsAzzurra Lazzeretti
24 shared publications- Barbara Stecca
Core Research Laboratory - Institute for Cancer Research and Prevention (ISPRO), Florence, Italy
24 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary material from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
Supplementary material and supplementary tables
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary material from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
Supplementary material and supplementary tables
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
- Open Access
- 10 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary material from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
Supplementary material and supplementary tables
- 10 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary material from Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
Supplementary material and supplementary tables